Genetic vs Genomic Part II: Integrating Comprehensive Testing ResultsContains 3 Component(s)
This on-demand webinar will take a deep dive into the differences between germline and somatic mutations and what this means for patients with cancer and their families.
Oral Agents for Advanced Hormone Receptor Positive Breast CancerContains 5 Component(s), Includes Credits
Component Credit Type State/Medical Type Available Credits Earned Credits CME/CNE/Certificate of Participation Medical CME 1.00 0.00 CME/CNE/Certificate of Participation Medical CNE 1.00 0.00 CME/CNE/Certificate of Participation Medical Certificate of Participation 1.00 0.00
A 3-member faculty panel will discuss treatment decisions for clinical case scenarios in advanced HR+ breast cancer. The panel will discuss challenging cases of patients and will offer guidance on evidence-based treatment choices for patients in the various lines of treatment and for managing treatment-related severe adverse events in these patients.
Pathology 101Contains 4 Component(s)
Learn more about the role of laboratory medicine professionals and pathologists, including a review of testing techniques and applications as well as lab-specific regulations and their impact on biomarker testing.
Quality Improvement in Breast Cancer Testing: Highlights from ACCC Member ProgramsContains 4 Component(s)
Hear finding and experiences of ACCC member programs who successfully orchestrated a quality improvement project to expand BRCA testing for eligible patients with breast cancer.
Integrating the Community Voice to Advance Cancer ResearchContains 3 Component(s)
Optimal care delivery changes from place to place—what works best for one location and patient population may not be ideal for another. The same applies to cancer research. Understanding the needs of your patient population is critical to trial design and implementation. How can you proactively involve your community in cancer research activities?
Emerging Therapies for the Management of Castration - Sensitive Prostate CancerContains 5 Component(s), Includes Credits
Component Credit Type State/Medical Type Available Credits Earned Credits CME/CPE/CNE/Certificate of Participation Medical CME 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical CPE 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical CNE 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical Certificate of Participation 1.00 0.00
With recent drug approvals and updates to clinical practice guidelines, many oncology practitioners find it challenging to stay abreast of changing treatment recommendations for patients with mCSPC (metastatic castration-sensitive prostate cancer). This activity aims to provide guidance on the latest in optimal management of mCSPC for oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The course will address challenges in optimal sequencing of care in mCSPC and will provide learners an opportunity to hear from experts regarding new research and clinical updates that can be translated into patient care strategies.
The Role of Tissue Acquisition in Advancing Community Precision OncologyContains 3 Component(s)
Community cancer centers are fast becoming sites for biomarker testing and precision medicine. As clinical research becomes a larger part of community cancer center operations, strengthening tissue collection procedures and considering the establishment of biospecimen repositories are critical concerns.
MRD Clinical Updates in Chronic Lymphocytic LeukemiaContains 3 Component(s)
A panel of hematologic malignancy experts provide important and practical information for the assessment of measurable residual disease (MRD) as part of routine clinical practice for their patients with chronic lymphocytic leukemia.
Big Data In Immuno-OncologyContains 7 Component(s)
Tune into sessions from the ACCC Big Data in IO Workshop, where expert faculty will delve into role of data in managing immune-related adverse events; applications of clinical trial and real-world data; the evolving integration of molecular data and patient-reported outcomes; and how new technologies will impact the future of data in immuno-oncology.
|Access Date||Quiz Result||Score||Actions|